DV Trading LLC Acquires New Shares in CytomX Therapeutics, Inc. $CTMX

DV Trading LLC acquired a new position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 714,000 shares of the biotechnology company’s stock, valued at approximately $3,356,000. CytomX Therapeutics accounts for approximately 0.1% of DV Trading LLC’s investment portfolio, making the stock its 19th largest holding.

Other hedge funds have also recently bought and sold shares of the company. Squarepoint Ops LLC raised its holdings in CytomX Therapeutics by 4.5% during the fourth quarter. Squarepoint Ops LLC now owns 49,897 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 2,169 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of CytomX Therapeutics by 83.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,000 shares in the last quarter. Velan Capital Investment Management LP boosted its stake in shares of CytomX Therapeutics by 6.7% during the 3rd quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 5,000 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of CytomX Therapeutics during the 4th quarter valued at about $35,000. Finally, Raymond James Financial Inc. increased its holdings in shares of CytomX Therapeutics by 3.5% during the 3rd quarter. Raymond James Financial Inc. now owns 293,560 shares of the biotechnology company’s stock valued at $936,000 after acquiring an additional 10,000 shares during the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Stock Performance

NASDAQ CTMX opened at $3.10 on Friday. CytomX Therapeutics, Inc. has a twelve month low of $1.72 and a twelve month high of $8.21. The stock has a market capitalization of $527.59 million, a PE ratio of -7.56 and a beta of 2.08. The stock has a 50-day simple moving average of $3.39 and a 200 day simple moving average of $4.31.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04. The firm had revenue of $10.26 million during the quarter, compared to the consensus estimate of $4.68 million. CytomX Therapeutics had a negative return on equity of 36.61% and a negative net margin of 166.40%. As a group, equities research analysts forecast that CytomX Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on CTMX shares. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a report on Tuesday, June 16th. HC Wainwright lowered their price target on CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Wolfe Research initiated coverage on shares of CytomX Therapeutics in a research report on Tuesday, May 19th. They issued an “outperform” rating and a $6.00 price target on the stock. Wall Street Zen upgraded shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Zacks Research raised shares of CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $12.10.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.